[S02DA03, antipyrine, The risk or severity of hyperkalemia can be increased when Antipyrine is combined with Cyclandelate.]
[L04AA27, fingolimod, Cyclandelate may increase the bradycardic activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Cyclandelate.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Sulfamethoxazole.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of hyperkalemia can be increased when Sulindac is combined with Cyclandelate.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Glymidine.]
[M01AX04, apazone, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Azapropazone.]
[N05CA19, thiopental, The metabolism of Cyclandelate can be increased when combined with Thiopental.]
[N05AB08, thioproperazine, The risk or severity of hypotension can be increased when Thioproperazine is combined with Cyclandelate.]
[N05AC02, thioridazine, The risk or severity of hypotension can be increased when Thioridazine is combined with Cyclandelate.]
[C01BB04, aprindine, Aprindine may increase the arrhythmogenic activities of Cyclandelate.]
[S01ED01, timolol, The risk or severity of adverse effects can be increased when Cyclandelate is combined with Timolol.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Tolazamide.]
[M02AX02, tolazoline, The risk or severity of hypotension can be increased when Tolazoline is combined with Cyclandelate.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of hyperkalemia can be increased when Tolmetin is combined with Cyclandelate.]
[N06AX05, trazodone, The risk or severity of hypotension can be increased when Trazodone is combined with Cyclandelate.]
[C03DB02, triamterene, The risk or severity of hyperkalemia can be increased when Triamterene is combined with Cyclandelate.]
[N05AB06, trifluoperazine, The risk or severity of hypotension can be increased when Trifluoperazine is combined with Cyclandelate.]
[A03AA05, trimebutine, Cyclandelate may increase the arrhythmogenic activities of Trimebutine.]
[S01ED04, metipranolol, Cyclandelate may increase the arrhythmogenic activities of Metipranolol.]
[N03AC02, trimethadione, Trimethadione may increase the arrhythmogenic activities of Cyclandelate.]
[J01EA01, trimethoprim, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Cyclandelate.]
[N06AA06, trimipramine, The risk or severity of hypotension can be increased when Trimipramine is combined with Cyclandelate.]
[J01FA08, troleandomycin, The metabolism of Cyclandelate can be decreased when combined with Troleandomycin.]
[C09CA09, azilsartan medoxomil, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Azilsartan medoxomil.]
[M03AA02, tubocurarine, Cyclandelate may increase the neuromuscular blocking activities of Tubocurarine.]
[A10BH05, linagliptin, The metabolism of Cyclandelate can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The serum concentration of Cyclandelate can be increased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Cyclandelate can be decreased when combined with Telaprevir.]
[C08DA01, verapamil, Verapamil may increase the arrhythmogenic activities of Cyclandelate.]
[N06AX09, viloxazine, The metabolism of Cyclandelate can be decreased when combined with Viloxazine.]
[N05AF05, zuclopenthixol, The risk or severity of hypotension can be increased when Zuclopenthixol is combined with Cyclandelate.]
[J05AE02, indinavir, The metabolism of Cyclandelate can be decreased when combined with Indinavir.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Cyclandelate.]
[N05AE04, ziprasidone, The risk or severity of hypotension can be increased when Ziprasidone is combined with Cyclandelate.]
[G03AC10, drospirenone, The risk or severity of hyperkalemia can be increased when Drospirenone is combined with Cyclandelate.]
[N02BA01, aspirin, The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Cyclandelate.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Cyclandelate.]
[C07AB03, atenolol, Atenolol may increase the arrhythmogenic activities of Cyclandelate.]
[J02AC03, voriconazole, The metabolism of Cyclandelate can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, Cyclandelate may increase the neuromuscular blocking activities of Atracurium.]
[S01FA01, atropine, Atropine may increase the arrhythmogenic activities of Cyclandelate.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Cyclandelate.]
[V03AX03, cobicistat, The metabolism of Cyclandelate can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Cyclandelate can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Cyclandelate can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Cyclandelate.]
[A02AA05, magnesium silicate, The risk or severity of hypotension can be increased when Magnesium silicate is combined with Cyclandelate.]
[L01EX05, regorafenib, Cyclandelate may increase the bradycardic activities of Regorafenib.]
[N05CA04, barbital, The metabolism of Cyclandelate can be increased when combined with Barbital.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may increase the arrhythmogenic activities of Cyclandelate.]
[J05AE04, nelfinavir, The metabolism of Cyclandelate can be decreased when combined with Nelfinavir.]
[C08CA13, lercanidipine, Lercanidipine may increase the arrhythmogenic activities of Cyclandelate.]
[N06DA02, donepezil, Donepezil may increase the bradycardic activities of Cyclandelate.]
[L04AA29, tofacitinib, Cyclandelate may increase the bradycardic activities of Tofacitinib.]
[H01CB05, pasireotide, Cyclandelate may increase the bradycardic activities of Pasireotide.]
[C04AX11, bencyclane, Cyclandelate may increase the arrhythmogenic activities of Bencyclane.]
[A10BH04, alogliptin, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Alogliptin.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the bradycardic activities of Cyclandelate.]
[N02BA10, benorilate, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Benorilate.]
[A10BK02, canagliflozin, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Canagliflozin.]
[A12CC09, magnesium orotate, The risk or severity of hypotension can be increased when Magnesium orotate is combined with Cyclandelate.]
[A06AX06, tegaserod, The therapeutic efficacy of Tegaserod can be decreased when used in combination with Cyclandelate.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Insulin detemir.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Pramlintide.]
[M01AH01, celecoxib, The risk or severity of hyperkalemia can be increased when Celecoxib is combined with Cyclandelate.]
[A12CC05, magnesium aspartate, The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Cyclandelate.]
[L01EC02, dabrafenib, The serum concentration of Cyclandelate can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Benzydamine.]
[C08EA02, bepridil, Bepridil may increase the arrhythmogenic activities of Cyclandelate.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Lixisenatide.]
[J05AP05, simeprevir, The metabolism of Cyclandelate can be decreased when combined with Simeprevir.]
[A10BK01, dapagliflozin, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Dapagliflozin.]
[C07AB04, acebutolol, Acebutolol may increase the arrhythmogenic activities of Cyclandelate.]
[A16AA07, metreleptin, The metabolism of Cyclandelate can be increased when combined with Metreleptin.]
[S01ED02, betaxolol, Betaxolol may increase the arrhythmogenic activities of Cyclandelate.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Albiglutide.]
[L01ED02, ceritinib, Cyclandelate may increase the bradycardic activities of Ceritinib.]
[A03BA03, hyoscyamine, Hyoscyamine may increase the arrhythmogenic activities of Cyclandelate.]
[A10BK03, empagliflozin, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Empagliflozin.]
[N05AA04, acepromazine, The risk or severity of hypotension can be increased when Acepromazine is combined with Cyclandelate.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Cyclandelate.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Dulaglutide.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Cyclandelate.]
[C01EB17, ivabradine, Cyclandelate may increase the bradycardic activities of Ivabradine.]
[N05AX16, brexpiprazole, The risk or severity of hypotension can be increased when Brexpiprazole is combined with Cyclandelate.]
[A06AD03, magnesium peroxide, The risk or severity of hypotension can be increased when Magnesium peroxide is combined with Cyclandelate.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Acarbose.]
[M02AA25, aceclofenac, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Acemetacin.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Insulin degludec.]
[J02AC05, isavuconazole, The metabolism of Cyclandelate can be decreased when combined with Isavuconazole.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Acetohexamide.]
[G04CA01, alfuzosin, The risk or severity of hypotension can be increased when Alfuzosin is combined with Cyclandelate.]
[M01AE16, alminoprofen, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Alminoprofen.]
[L01XX52, venetoclax, The metabolism of Cyclandelate can be decreased when combined with Venetoclax.]
[N04BC01, bromocriptine, The risk or severity of hypotension can be increased when Bromocriptine is combined with Cyclandelate.]
[C08CA01, amlodipine, Amlodipine may increase the arrhythmogenic activities of Cyclandelate.]
[C07AA19, bupranolol, Cyclandelate may increase the arrhythmogenic activities of Bupranolol.]
[N06DA03, rivastigmine, Rivastigmine may increase the bradycardic activities of Cyclandelate.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Cyclandelate.]
[L01EF02, ribociclib, The metabolism of Cyclandelate can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hyperkalemia can be increased when Balsalazide is combined with Cyclandelate.]
[N02BF02, pregabalin, Pregabalin may increase the bradycardic activities of Cyclandelate.]
[C09AA07, benazepril, The risk or severity of hyperkalemia can be increased when Benazepril is combined with Cyclandelate.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Benfluorex.]
[G04BA03, calcium chloride, The therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium chloride.]
[J05AE09, tipranavir, The metabolism of Cyclandelate can be decreased when combined with Tipranavir.]
[D11AX03, calcium gluconate, The therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium gluconate.]
[L01EX10, midostaurin, The metabolism of Cyclandelate can be decreased when combined with Midostaurin.]
[D01AC10, bifonazole, The therapeutic efficacy of Bifonazole can be increased when used in combination with Cyclandelate.]
[P03AC02, bioallethrin, Cyclandelate may increase the arrhythmogenic activities of Bioallethrin.]
[C07AB07, bisoprolol, The therapeutic efficacy of Cyclandelate can be increased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The serum concentration of Cyclandelate can be decreased when it is combined with Efavirenz.]
[C07AA17, bopindolol, The risk or severity of bradycardia can be increased when Cyclandelate is combined with Bopindolol.]
[C03DA03, canrenone, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Canrenone.]
[M01AB07, bumadizone, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Bumadizone.]
[C01AA02, acetyldigoxins, Cyclandelate may increase the arrhythmogenic activities of Acetyldigoxin.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Semaglutide.]
[A10BK04, ertugliflozin, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Ertugliflozin.]
[C09AA01, captopril, The risk or severity of hyperkalemia can be increased when Captopril is combined with Cyclandelate.]
[L02BB05, apalutamide, The metabolism of Cyclandelate can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Cyclandelate can be increased when combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Cyclandelate.]
[C07AG02, carvedilol, Carvedilol may increase the arrhythmogenic activities of Cyclandelate.]
[C07AB08, celiprolol, Cyclandelate may increase the arrhythmogenic activities of Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Cyclandelate can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Cyclandelate can be decreased when combined with Stiripentol.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Carbutamide.]
[M01AC05, lornoxicam, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Lornoxicam.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Cyclandelate.]
[C01BG07, cifenline, Cyclandelate may increase the arrhythmogenic activities of Cibenzoline.]
[C09AA08, cilazapril, The risk or severity of hyperkalemia can be increased when Cilazapril is combined with Cyclandelate.]
[S01ED05, carteolol, Cyclandelate may increase the arrhythmogenic activities of Carteolol.]
[J01FA09, clarithromycin, The metabolism of Cyclandelate can be decreased when combined with Clarithromycin.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Cyclandelate.]
[V03AE07, calcium acetate, The therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium acetate.]
[C09CA06, candesartan, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Candesartan.]
[A12CC06, magnesium lactate, The risk or severity of hypotension can be increased when Magnesium lactate is combined with Cyclandelate.]
[C03BX03, cicletanine, Cyclandelate may increase the arrhythmogenic activities of Cicletanine.]
[N07XX11, pitolisant, The serum concentration of Cyclandelate can be decreased when it is combined with Pitolisant.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Insulin pork.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Cyclandelate.]
[N02CC08, lasmiditan, Lasmiditan may increase the bradycardic activities of Cyclandelate.]
[N03AX25, cenobamate, The serum concentration of Cyclandelate can be decreased when it is combined with Cenobamate.]
[J05AE05, amprenavir, The metabolism of Cyclandelate can be decreased when combined with Amprenavir.]
[M01AH02, rofecoxib, The risk or severity of hyperkalemia can be increased when Rofecoxib is combined with Cyclandelate.]
[C08CA16, clevidipine, Cyclandelate may increase the arrhythmogenic activities of Clevidipine.]
[C01BD07, dronedarone, Cyclandelate may increase the arrhythmogenic activities of Dronedarone.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Cyclandelate.]
[M01AC04, droxicam, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Droxicam.]
[M02AA27, dexketoprofen, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Dexketoprofen.]
[L04AC19, satralizumab, The serum concentration of Cyclandelate can be decreased when it is combined with Satralizumab.]
[N05AA01, chlorpromazine, The risk or severity of hypotension can be increased when Chlorpromazine is combined with Cyclandelate.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Chlorpropamide.]
[N02BA07, ethenzamide, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Ethenzamide.]
[N06BX18, vinpocetine, Cyclandelate may increase the arrhythmogenic activities of Vinpocetine.]
[M01AB08, etodolac, The risk or severity of hyperkalemia can be increased when Etodolac is combined with Cyclandelate.]
[M02AA06, etofenamate, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Cyclandelate can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Cyclandelate can be decreased when combined with Lonafarnib.]
[M09AA01, hydroquinine, Cyclandelate may increase the arrhythmogenic activities of Hydroquinine.]
[P03AX07, abametapir, The serum concentration of Cyclandelate can be increased when it is combined with Abametapir.]
[M01AE05, fenbufen, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Fenbufen.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Cyclandelate.]
[A02BA01, cimetidine, The serum concentration of Cyclandelate can be increased when it is combined with Cimetidine.]
[N07CA02, cinnarizine, Cinnarizine may increase the arrhythmogenic activities of Cyclandelate.]
[L01XX73, sotorasib, The serum concentration of Cyclandelate can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Cyclandelate can be decreased when combined with Ciprofloxacin.]
[C03DA05, finerenone, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Finerenone.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Cyclandelate is combined with Fexinidazole.]
[A10BB12, glimepiride, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Glimepiride.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Gliquidone.]
[A12AA02, calcium glubionate, The therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium glubionate anhydrous.]
[N06AX25, St. John's wort extract, The metabolism of Cyclandelate can be increased when combined with St. John's Wort.]
[S01EA04, clonidine, Clonidine may increase the atrioventricular blocking (AV block) activities of Cyclandelate.]
[C01EB24, mavacamten, The serum concentration of Cyclandelate can be decreased when it is combined with Mavacamten.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Tirzepatide.]
[J02AC06, oteseconazole, The therapeutic efficacy of Oteseconazole can be increased when used in combination with Cyclandelate.]
[N05AH02, clozapine, The risk or severity of hypotension can be increased when Clozapine is combined with Cyclandelate.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Sotagliflozin.]
[H01AC08, somatrogon, The metabolism of Cyclandelate can be increased when combined with Somatrogon.]
[M01AX13, proquazone, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Proquazone.]
[C01BA13, hydroquinidine, Cyclandelate may increase the arrhythmogenic activities of Hydroquinidine.]
[A02AD04, hydrotalcite, The risk or severity of hypotension can be increased when Hydrotalcite is combined with Cyclandelate.]
[A04AA03, tropisetron, Cyclandelate may increase the arrhythmogenic activities of Tropisetron.]
[A10BX03, nateglinide, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Cyclandelate can be decreased when combined with Telithromycin.]
[B01AC10, indobufen, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Indobufen.]
[M01AH03, valdecoxib, The risk or severity of hyperkalemia can be increased when Valdecoxib is combined with Cyclandelate.]
[C01AA06, lanatoside C, The serum concentration of Lanatoside C can be increased when it is combined with Cyclandelate.]
[M01AH04, parecoxib, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Cyclandelate can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Bemiparin.]
[M01AA06, kebuzone, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Kebuzone.]
[J02AC04, posaconazole, The metabolism of Cyclandelate can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, Cyclandelate may increase the arrhythmogenic activities of Lacidipine.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Cyclandelate.]
[N03AX09, lamotrigine, Lamotrigine may increase the arrhythmogenic activities of Cyclandelate.]
[M01AB09, lonazolac, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Loxoprofen.]
[C09AA03, lisinopril, The risk or severity of hyperkalemia can be increased when Lisinopril is combined with Cyclandelate.]
[A02AD02, magaldrate, The risk or severity of hypotension can be increased when Magaldrate is combined with Cyclandelate.]
[A06AD01, magnesium carbonate, The risk or severity of hypotension can be increased when Magnesium carbonate is combined with Cyclandelate.]
[C08CA11, manidipine, Cyclandelate may increase the arrhythmogenic activities of Manidipine.]
[C07AA14, mepindolol, The risk or severity of bradycardia can be increased when Cyclandelate is combined with Mepindolol.]
[C01EB10, adenosine, Adenosine may increase the arrhythmogenic activities of Cyclandelate.]
[S01AA13, fusidic acid, The metabolism of Cyclandelate can be decreased when combined with Fusidic acid.]
[M01AG01, mefenamic acid, The risk or severity of hyperkalemia can be increased when Mefenamic acid is combined with Cyclandelate.]
[C03DA04, eplerenone, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Cyclandelate.]
[N05AD03, metylperon, Cyclandelate may increase the arrhythmogenic activities of Melperone.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Miglitol.]
[S01XA18, cyclosporine, The metabolism of Cyclandelate can be decreased when combined with Cyclosporine.]
[C09AA13, moexipril, The risk or severity of hyperkalemia can be increased when Moexipril is combined with Cyclandelate.]
[M02AA02, mofebutazone, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Cyclandelate can be decreased when combined with Conivaptan.]
[M01AH05, etoricoxib, The risk or severity of hyperkalemia can be increased when Etoricoxib is combined with Cyclandelate.]
[G03XA01, danazol, The metabolism of Cyclandelate can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Cyclandelate.]
[M01AX01, nabumetone, The risk or severity of hyperkalemia can be increased when Nabumetone is combined with Cyclandelate.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Cyclandelate.]
[C07AB12, nebivolol, Cyclandelate may increase the arrhythmogenic activities of Nebivolol.]
[N06AX06, nefazodone, The metabolism of Cyclandelate can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Cyclandelate may increase the arrhythmogenic activities of Nicorandil.]
[M03AC11, cisatracurium, Cyclandelate may increase the neuromuscular blocking activities of Cisatracurium.]
[A07EC03, olsalazine, The risk or severity of hyperkalemia can be increased when Olsalazine is combined with Cyclandelate.]
[C01AA07, deslanoside, Deslanoside may increase the arrhythmogenic activities of Cyclandelate.]
[C09XA02, aliskiren, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hyperkalemia can be increased when Oxaprozin is combined with Cyclandelate.]
[S03BA01, dexamethasone, The metabolism of Cyclandelate can be increased when combined with Dexamethasone.]
[B01AC04, clopidogrel, The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Cyclandelate.]
[C01DA05, pentaerythritol tetranitrate, Cyclandelate may increase the vasodilatory activities of Pentaerythritol tetranitrate.]
[S01BC03, diclofenac, The risk or severity of hyperkalemia can be increased when Diclofenac is combined with Cyclandelate.]
[A03AX04, pinaverium, Cyclandelate may increase the arrhythmogenic activities of Pinaverium.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Pioglitazone.]
[C08CA03, isradipine, Isradipine may increase the arrhythmogenic activities of Cyclandelate.]
[N02BA11, diflunisal, The risk or severity of hyperkalemia can be increased when Diflunisal is combined with Cyclandelate.]
[C01AA04, digitoxin, Digitoxin may increase the arrhythmogenic activities of Cyclandelate.]
[C01AA05, digoxin, Digoxin may increase the arrhythmogenic activities of Cyclandelate.]
[N02CA01, dihydroergotamine, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Cyclandelate.]
[J05AE08, atazanavir, The metabolism of Cyclandelate can be decreased when combined with Atazanavir.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Cyclandelate.]
[C08DB01, diltiazem, Diltiazem may increase the arrhythmogenic activities of Cyclandelate.]
[N02BB04, propyphenazone, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Proglumetacin.]
[C09AA06, quinapril, The risk or severity of hyperkalemia can be increased when Quinapril is combined with Cyclandelate.]
[C09AA05, ramipril, The risk or severity of hyperkalemia can be increased when Ramipril is combined with Cyclandelate.]
[S01XA23, sirolimus, Cyclandelate may increase the immunosuppressive activities of Sirolimus.]
[C01BA03, disopyramide, Disopyramide may increase the arrhythmogenic activities of Cyclandelate.]
[S02AA12, rifamycin SV, The metabolism of Cyclandelate can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Cyclandelate can be increased when combined with Rifapentine.]
[N05AX08, risperidone, The risk or severity of hypotension can be increased when Risperidone is combined with Cyclandelate.]
[L01EX01, sunitinib, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Cyclandelate can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Tolvaptan.]
[S01BC05, ketorolac, The risk or severity of hyperkalemia can be increased when Ketorolac is combined with Cyclandelate.]
[N02BA06, salsalate, The risk or severity of hyperkalemia can be increased when Salsalate is combined with Cyclandelate.]
[N06AA12, doxepin, The risk or severity of hypotension can be increased when Doxepin is combined with Cyclandelate.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Cyclandelate.]
[N01AB08, sevoflurane, The risk or severity of hypotension can be increased when Sevoflurane is combined with Cyclandelate.]
[N05AD08, droperidol, The risk or severity of hypotension can be increased when Droperidol is combined with Cyclandelate.]
[V03AG05, sodium phosphate, Sodium phosphate, monobasic may increase the hyperkalemic activities of Cyclandelate.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Cyclandelate.]
[C09AA11, spirapril, The risk or severity of hyperkalemia can be increased when Spirapril is combined with Cyclandelate.]
[C07AB13, talinolol, Cyclandelate may increase the arrhythmogenic activities of Talinolol.]
[M01AC02, tenoxicam, The risk or severity of hyperkalemia can be increased when Tenoxicam is combined with Cyclandelate.]
[G04CA03, terazosin, The risk or severity of hypotension can be increased when Terazosin is combined with Cyclandelate.]
[G04BD05, terodiline, Cyclandelate may increase the arrhythmogenic activities of Terodiline.]
[C07AA16, tertatolol, Cyclandelate may increase the arrhythmogenic activities of Tertatolol.]
[C09AA02, enalapril, The risk or severity of hyperkalemia can be increased when Enalapril is combined with Cyclandelate.]
[M01AG02, tolfenamic acid, Cyclandelate may increase the bradycardic activities of Tolfenamic acid.]
[C09AA10, trandolapril, The risk or severity of hyperkalemia can be increased when Trandolapril is combined with Cyclandelate.]
[C02CA06, urapidil, The risk or severity of hypotension can be increased when Urapidil is combined with Cyclandelate.]
[S01GA03, xylometazoline, Cyclandelate may increase the arrhythmogenic activities of Xylometazoline.]
[C08CA12, mepirodipine, Cyclandelate may increase the arrhythmogenic activities of Barnidipine.]
[C09AA15, zofenopril, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Zofenopril.]
[M01AB04, zomepirac, The risk or severity of hyperkalemia can be increased when Zomepirac is combined with Cyclandelate.]
[N03AX15, zonisamide, Zonisamide may increase the arrhythmogenic activities of Cyclandelate.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Insulin glulisine.]
[C02AC02, guanfacine, Guanfacine may increase the bradycardic activities of Cyclandelate.]
[C01BG01, moricizine, Moricizine may increase the arrhythmogenic activities of Cyclandelate.]
[N02CA02, ergotamine, The metabolism of Cyclandelate can be decreased when combined with Ergotamine.]
[C01DA13, erythrityl tetranitrate, Cyclandelate may increase the vasodilatory activities of Erythrityl tetranitrate.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Cyclandelate.]
[C01BD05, ibutilide, Ibutilide may increase the arrhythmogenic activities of Cyclandelate.]
[N03AD01, ethosuximide, Ethosuximide may increase the arrhythmogenic activities of Cyclandelate.]
[M01AC06, meloxicam, The risk or severity of hyperkalemia can be increased when Meloxicam is combined with Cyclandelate.]
[C01BA05, ajmaline, Ajmaline may increase the arrhythmogenic activities of Cyclandelate.]
[L04AD02, tacrolimus, Cyclandelate may increase the immunosuppressive activities of Tacrolimus.]
[R06AX12, terfenadine, The metabolism of Cyclandelate can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Cyclandelate can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, Tocainide may increase the arrhythmogenic activities of Cyclandelate.]
[C01BC08, encainide, Encainide may increase the arrhythmogenic activities of Cyclandelate.]
[C08CA02, felodipine, Felodipine may increase the arrhythmogenic activities of Cyclandelate.]
[C08EA01, fendiline, Cyclandelate may increase the arrhythmogenic activities of Fendiline.]
[M01AE04, fenoprofen, The risk or severity of hyperkalemia can be increased when Fenoprofen is combined with Cyclandelate.]
[N02AB03, fentanyl, Fentanyl may increase the bradycardic activities of Cyclandelate.]
[C01BC04, flecainide, Flecainide may increase the arrhythmogenic activities of Cyclandelate.]
[N02BG04, floctafenine, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Cyclandelate can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, Cyclandelate may increase the arrhythmogenic activities of Flunarizine.]
[N05AF01, flupenthixol, The risk or severity of hypotension can be increased when Flupentixol is combined with Cyclandelate.]
[S01BC04, flurbiprofen, The risk or severity of hyperkalemia can be increased when Flurbiprofen is combined with Cyclandelate.]
[N05AG01, fluspirilene, Cyclandelate may increase the arrhythmogenic activities of Fluspirilene.]
[M03AA01, alcuronium, Cyclandelate may increase the neuromuscular blocking activities of Alcuronium.]
[J05AE10, darunavir, The serum concentration of Cyclandelate can be increased when it is combined with Darunavir.]
[N06DA04, galantamine, Galantamine may increase the bradycardic activities of Cyclandelate.]
[M03AC02, gallamine, Cyclandelate may increase the neuromuscular blocking activities of Gallamine.]
[C08DA02, gallopamil, Cyclandelate may increase the arrhythmogenic activities of Gallopamil.]
[N03AA04, barbexaclone, The metabolism of Cyclandelate can be increased when combined with Barbexaclone.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Liraglutide.]
[A12AA10, calcium gluceptate, The therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium glucoheptonate.]
[A12AA30, calcium levulinate, The therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium levulinate.]
[N03AD03, methsuximide, Cyclandelate may increase the arrhythmogenic activities of Methsuximide.]
[N01AH02, alfentanil, Alfentanil may increase the bradycardic activities of Cyclandelate.]
[A10BB01, glyburide, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Glyburide.]
[A10BB09, gliclazide, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Gliclazide.]
[A10BB07, glipizide, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Glipizide.]
[N05CM18, dexmedetomidine, Dexmedetomidine may increase the bradycardic activities of Cyclandelate.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Cyclandelate.]
[C05AE01, nitroglycerin, Cyclandelate may increase the vasodilatory activities of Nitroglycerin.]
[C01BD04, dofetilide, Dofetilide may increase the arrhythmogenic activities of Cyclandelate.]
[C02CA04, doxazosin, The risk or severity of hypotension can be increased when Doxazosin is combined with Cyclandelate.]
[C07AB09, esmolol, Esmolol may increase the arrhythmogenic activities of Cyclandelate.]
[C09AA09, fosinopril, The risk or severity of hyperkalemia can be increased when Fosinopril is combined with Cyclandelate.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Cyclandelate.]
[N05AH04, quetiapine, The risk or severity of hypotension can be increased when Quetiapine is combined with Cyclandelate.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Insulin aspart.]
[C09CA01, losartan, Losartan may increase the arrhythmogenic activities of Cyclandelate.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Heparin is combined with Cyclandelate.]
[B05CB03, magnesium citrate, The risk or severity of hypotension can be increased when Magnesium citrate is combined with Cyclandelate.]
[A12CC03, magnesium gluconate, The risk or severity of hypotension can be increased when Magnesium gluconate is combined with Cyclandelate.]
[A07EC02, mesalamine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Cyclandelate.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Cyclandelate.]
[N05CA16, hexobarbital, The metabolism of Cyclandelate can be increased when combined with Hexobarbital.]
[C08CA10, nilvadipine, Cyclandelate may increase the arrhythmogenic activities of Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may increase the arrhythmogenic activities of Cyclandelate.]
[C09AA04, perindopril, The risk or severity of hyperkalemia can be increased when Perindopril is combined with Cyclandelate.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Cyclandelate.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Cyclandelate.]
[A12BA02, potassium citrate, Potassium citrate may increase the hyperkalemic activities of Cyclandelate.]
[G04BD06, propiverine, The risk or severity of hypotension can be increased when Propiverine is combined with Cyclandelate.]
[R02AX02, ibuprofen, The risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Cyclandelate.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Cyclandelate.]
[N01AH03, sufentanil, Sufentanil may increase the bradycardic activities of Cyclandelate.]
[N06AA02, imipramine, The risk or severity of hypotension can be increased when Imipramine is combined with Cyclandelate.]
[M03BX02, tizanidine, Tizanidine may increase the bradycardic activities of Cyclandelate.]
[S01BC01, indomethacin, The risk or severity of hyperkalemia can be increased when Indomethacin is combined with Cyclandelate.]
[C02CA02, indoramin, The risk or severity of hypotension can be increased when Indoramin is combined with Cyclandelate.]
[N06AX17, milnacipran, The metabolism of Cyclandelate can be decreased when combined with Milnacipran.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Sitagliptin.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Vildagliptin.]
[C07AA01, alprenolol, Alprenolol may increase the arrhythmogenic activities of Cyclandelate.]
[C09AA16, imidapril, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Imidapril.]
[J04AC01, isoniazid, The metabolism of Cyclandelate can be decreased when combined with Isoniazid.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Exenatide.]
[C05AE02, isosorbide dinitrate, Cyclandelate may increase the vasodilatory activities of Isosorbide dinitrate.]
[J02AB02, ketoconazole, The metabolism of Cyclandelate can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of hypotension can be increased when Olanzapine is combined with Cyclandelate.]
[M02AA10, ketoprofen, The risk or severity of hyperkalemia can be increased when Ketoprofen is combined with Cyclandelate.]
[M01AE11, tiaprofenic acid, The risk or severity of hyperkalemia can be increased when Tiaprofenic acid is combined with Cyclandelate.]
[C07AG01, labetalol, The risk or severity of bradycardia can be increased when Cyclandelate is combined with Labetalol.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Cyclandelate.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Cyclandelate.]
[N03AX18, lacosamide, Cyclandelate may increase the bradycardic activities of Lacosamide.]
[S02DA01, lidocaine, Lidocaine may increase the arrhythmogenic activities of Cyclandelate.]
[C08EX01, lidoflazine, Cyclandelate may increase the arrhythmogenic activities of Lidoflazine.]
[C03DB01, amiloride, The risk or severity of hyperkalemia can be increased when Amiloride is combined with Cyclandelate.]
[A07DA03, loperamide, Loperamide may increase the arrhythmogenic activities of Cyclandelate.]
[C10AA02, lovastatin, The metabolism of Cyclandelate can be decreased when combined with Lovastatin.]
[B05XA11, magnesium chloride, The risk or severity of hypotension can be increased when Magnesium chloride is combined with Cyclandelate.]
[G04BX01, magnesium hydroxide, The risk or severity of hypotension can be increased when Magnesium hydroxide is combined with Cyclandelate.]
[A12CC10, magnesium oxide, The risk or severity of hypotension can be increased when Magnesium oxide is combined with Cyclandelate.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the arrhythmogenic activities of Cyclandelate.]
[L01EA03, nilotinib, The metabolism of Cyclandelate can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of hyperkalemia can be increased when Mannitol is combined with Cyclandelate.]
[M02AA18, meclofenamic acid, The risk or severity of hyperkalemia can be increased when Meclofenamic acid is combined with Cyclandelate.]
[C01AA08, medigoxin, Cyclandelate may increase the arrhythmogenic activities of Metildigoxin.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Cyclandelate.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Cyclandelate.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Dalteparin.]
[N05CH01, melatonin, The therapeutic efficacy of Cyclandelate can be decreased when used in combination with Melatonin.]
[N03AA01, mephobarbital, The metabolism of Cyclandelate can be increased when combined with Methylphenobarbital.]
[N05AX13, paliperidone, The risk or severity of hypotension can be increased when Paliperidone is combined with Cyclandelate.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Metformin.]
[H01CB03, lanreotide, Cyclandelate may increase the bradycardic activities of Lanreotide.]
[H03BB02, methimazole, The metabolism of Cyclandelate can be decreased when combined with Methimazole.]
[N05CA15, methohexital, The metabolism of Cyclandelate can be increased when combined with Methohexital.]
[N02BG08, ziconotide, Cyclandelate may increase the arrhythmogenic activities of Ziconotide.]
[N05AA02, methotrimeprazine, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Cyclandelate.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Cyclandelate.]
[C02AB01, methyldopa, Methyldopa may increase the bradycardic activities of Cyclandelate.]
[C07AB02, metoprolol, Metoprolol may increase the arrhythmogenic activities of Cyclandelate.]
[C01BB02, mexiletine, Mexiletine may increase the arrhythmogenic activities of Cyclandelate.]
[S02AA13, miconazole, The metabolism of Cyclandelate can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hyperkalemia can be increased when Aminophenazone is combined with Cyclandelate.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Parnaparin.]
[C01CA17, midodrine, Midodrine may increase the bradycardic activities of Cyclandelate.]
[G03XB01, mifepristone, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Tinzaparin.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Cyclandelate.]
[C09CA03, valsartan, The risk or severity of hyperkalemia can be increased when Valsartan is combined with Cyclandelate.]
[L01XX23, mitotane, The metabolism of Cyclandelate can be increased when combined with Mitotane.]
[C01BD01, amiodarone, The risk or severity of adverse effects can be increased when Amiodarone is combined with Cyclandelate.]
[N06AA09, amitriptyline, The risk or severity of hypotension can be increased when Amitriptyline is combined with Cyclandelate.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Ammonium chloride.]
[M03AC03, vecuronium, Cyclandelate may increase the neuromuscular blocking activities of Vecuronium.]
[N05CA02, amobarbital, The metabolism of Cyclandelate can be increased when combined with Amobarbital.]
[G04CA04, silodosin, The risk or severity of hypotension can be increased when Silodosin is combined with Cyclandelate.]
[N06AA17, amoxapine, The risk or severity of hypotension can be increased when Amoxapine is combined with Cyclandelate.]
[N03AB05, fosphenytoin, The metabolism of Cyclandelate can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, Nadolol may increase the arrhythmogenic activities of Cyclandelate.]
[J01CF06, nafcillin, The therapeutic efficacy of Cyclandelate can be decreased when used in combination with Nafcillin.]
[V03AB15, naloxone, The metabolism of Cyclandelate can be decreased when combined with Naloxone.]
[M02AA12, naproxen, The risk or severity of hyperkalemia can be increased when Naproxen is combined with Cyclandelate.]
[A10BG01, troglitazone, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Troglitazone.]
[N01AH06, remifentanil, Remifentanil may increase the bradycardic activities of Cyclandelate.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Repaglinide.]
[C01CX08, levosimendan, Levosimendan may increase the arrhythmogenic activities of Cyclandelate.]
[N05AX14, iloperidone, The risk or severity of hypotension can be increased when Iloperidone is combined with Cyclandelate.]
[J02AA01, amphotericin B, Cyclandelate may decrease the nephrotoxic activities of Amphotericin B.]
[N06AX23, desvenlafaxine, The metabolism of Cyclandelate can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, The risk or severity of hyperkalemia can be increased when Telmisartan is combined with Cyclandelate.]
[C08CA04, nicardipine, Nicardipine may increase the arrhythmogenic activities of Cyclandelate.]
[C04AE02, nicergoline, The risk or severity of hypotension can be increased when Nicergoline is combined with Cyclandelate.]
[C08CA05, nifedipine, Nifedipine may increase the arrhythmogenic activities of Cyclandelate.]
[M02AA17, niflumic acid, The risk or severity of hyperkalemia can be increased when Niflumic acid is combined with Cyclandelate.]
[V03AB22, amyl nitrite, Cyclandelate may increase the vasodilatory activities of Amyl Nitrite.]
[C08CA06, nimodipine, Nimodipine may increase the arrhythmogenic activities of Cyclandelate.]
[C08CA07, nisoldipine, Nisoldipine may increase the arrhythmogenic activities of Cyclandelate.]
[C08CA08, nitrendipine, Nitrendipine may increase the arrhythmogenic activities of Cyclandelate.]
[J01XE01, nitrofurantoin, The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Cyclandelate.]
[C02DD01, nitroprusside, Cyclandelate may increase the hypotensive activities of Nitroprusside.]
[N06AA10, nortriptyline, The risk or severity of hypotension can be increased when Nortriptyline is combined with Cyclandelate.]
[G02CA02, nylidrin, Cyclandelate may increase the arrhythmogenic activities of Nylidrin.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Reviparin.]
[H01CB02, octreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Cyclandelate.]
[G04CA02, tamsulosin, The risk or severity of hypotension can be increased when Tamsulosin is combined with Cyclandelate.]
[C01AC01, ouabain, The serum concentration of Ouabain can be increased when it is combined with Cyclandelate.]
[C07AA02, oxprenolol, Oxprenolol may increase the arrhythmogenic activities of Cyclandelate.]
[S01BC02, oxyphenbutazone, The risk or severity of hyperkalemia can be increased when Oxyphenbutazone is combined with Cyclandelate.]
[N05AH05, asenapine, The risk or severity of hypotension can be increased when Asenapine is combined with Cyclandelate.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Danaparoid.]
[M03AC01, pancuronium, Cyclandelate may increase the neuromuscular blocking activities of Pancuronium.]
[C07AA23, penbutolol, The risk or severity of bradycardia can be increased when Cyclandelate is combined with Penbutolol.]
[N05AG03, penfluridol, Cyclandelate may increase the arrhythmogenic activities of Penfluridol.]
[N05CA01, pentobarbital, The metabolism of Cyclandelate can be increased when combined with Pentobarbital.]
[C08EX02, perhexiline, Perhexiline may increase the arrhythmogenic activities of Cyclandelate.]
[A10BA01, phenformin, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Phenformin.]
[N03AA02, phenobarbital, The metabolism of Cyclandelate can be increased when combined with Phenobarbital.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Cyclandelate.]
[C04AX02, phenoxybenzamine, The risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Cyclandelate.]
[V03AB36, phentolamine, The risk or severity of hypotension can be increased when Phentolamine is combined with Cyclandelate.]
[M02AA01, phenylbutazone, The risk or severity of hyperkalemia can be increased when Phenylbutazone is combined with Cyclandelate.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be decreased when Cyclandelate is combined with Phenylephrine.]
[N03AB02, phenytoin, The metabolism of Cyclandelate can be increased when combined with Phenytoin.]
[C08CX01, mibefradil, Mibefradil may increase the arrhythmogenic activities of Cyclandelate.]
[C07AA03, pindolol, The risk or severity of bradycardia can be increased when Cyclandelate is combined with Pindolol.]
[J05AE01, saquinavir, The metabolism of Cyclandelate can be decreased when combined with Saquinavir.]
[C09CA02, eprosartan, The risk or severity of hyperkalemia can be increased when Eprosartan is combined with Cyclandelate.]
[S01BC06, piroxicam, The risk or severity of hyperkalemia can be increased when Piroxicam is combined with Cyclandelate.]
[N02CX01, pizotyline, The risk or severity of hypotension can be increased when Pizotifen is combined with Cyclandelate.]
[J05AG02, delavirdine, The metabolism of Cyclandelate can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The risk or severity of hyperkalemia can be increased when Irbesartan is combined with Cyclandelate.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Rosiglitazone.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Cyclandelate.]
[J05AE03, ritonavir, The serum concentration of Cyclandelate can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Saxagliptin.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Cyclandelate.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Cyclandelate.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Insulin lispro.]
[C07AB01, practolol, Practolol may increase the arrhythmogenic activities of Cyclandelate.]
[C01BA08, prajmaline, Cyclandelate may increase the arrhythmogenic activities of Prajmaline.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Cyclandelate.]
[C01DX02, prenylamine, Prenylamine may increase the arrhythmogenic activities of Cyclandelate.]
[P01BA03, primaquine, The metabolism of Cyclandelate can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Cyclandelate can be increased when combined with Primidone.]
[C01BA02, procainamide, Procainamide may increase the arrhythmogenic activities of Cyclandelate.]
[N05AA03, promazine, The risk or severity of hypotension can be increased when Promazine is combined with Cyclandelate.]
[C01BC03, propafenone, Propafenone may increase the arrhythmogenic activities of Cyclandelate.]
[N05AC01, periciazine, The risk or severity of hypotension can be increased when Periciazine is combined with Cyclandelate.]
[N05CM06, propiomazine, The risk or severity of hypotension can be increased when Propiomazine is combined with Cyclandelate.]
[C07AA05, propranolol, Propranolol may increase the arrhythmogenic activities of Cyclandelate.]
[C01AB01, proscillaridin, The serum concentration of Proscillaridin can be increased when it is combined with Cyclandelate.]
[N05AX12, aripiprazole, The risk or severity of hypotension can be increased when Aripiprazole is combined with Cyclandelate.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Cyclandelate.]
[C01BA01, quinidine, Quinidine may increase the arrhythmogenic activities of Cyclandelate.]
[P01BC01, quinine, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Quinine.]
[C02AA01, rescinnamine, The risk or severity of hyperkalemia can be increased when Rescinnamine is combined with Cyclandelate.]
[J04AB02, rifampin, The metabolism of Cyclandelate can be increased when combined with Rifampicin.]
[N02BA05, salicylamide, The risk or severity of hyperkalemia can be increased when Cyclandelate is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hyperkalemia can be increased when Sulfasalazine is combined with Cyclandelate.]
[S01BC08, salicylic acid, The risk or severity of hyperkalemia can be increased when Salicylic acid is combined with Cyclandelate.]
[N05CA06, secobarbital, The metabolism of Cyclandelate can be increased when combined with Secobarbital.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Cyclandelate.]
[C07AA07, sotalol, Sotalol may increase the arrhythmogenic activities of Cyclandelate.]
[C03DA01, spironolactone, The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cyclandelate.]
[C01DA14, isosorbide mononitrate, Cyclandelate may increase the vasodilatory activities of Isosorbide mononitrate.]
[H02CA04, levoketoconazole, The metabolism of Cyclandelate can be decreased when combined with Levoketoconazole.]
[A12AA11, calcium pangamate, The therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium pangamate.]
